Bevacizumab, sorafenib tosylate and sunitinib for renal cell carcinoma: a systematic review and economic evaluation
Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K
Record ID 32010000102
English
Authors' recommendations:
Study found that bevacizumab, combined with interferon, and sunitinib have clinically relevant advantages over interferon alone in patients with metastatic renal cell carcinoma, temsirolimus has clinically relevant advantages over interferon in those with poor prognosis, and sorafenib tosylate is superior to best supportive care as second-line therapy, although none of the treatments was considered cost-effective at normal willingness to pay thresholds.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1711
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Angiogenesis Inhibitors
- Antineoplastic Agents
- Carcinoma, Renal Cell
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.